United States v. Steven Chun

Court of Appeals for the Eleventh Circuit·Decided August 18, 2026·No. 22-14192·Published

Opinion

FOR PUBLICATION

In the

United States Court of Appeals For the Eleventh Circuit

No. 22-14192

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus

STEVEN CHUN, DANIEL TONDRE, Defendants-Appellants.

Appeal from the United States District Court for the Middle District of Florida D.C. Docket No. 8:20-cr-00120-WFJ-JSS-1

Before NEWSOM, BRASHER, and TJOFLAT, Circuit Judges.

USCA11 Case: 22-14192 Document: 108-1 Date Filed: 08/18/2026 Page: 2 of 32

2 Opinion of the Court 22-14192

TJOFLAT, Circuit Judge:

BACKGROUND

In United States v. Simon, 12 F.4th 1 (1st Cir. 2021), the First Circuit affirmed the convictions of the founder and four executives of Insys Therapeutics, Inc. (“Insys”), 1 under the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1962(d), 2 for conspiring to bribe physicians to prescribe Subsys, a fentanyl-laced spray medication administered beneath the tongue. Insys developed, and the U.S. Food and Drug Administration (“FDA”) approved, Subsys in early 2012 for use in the treatment of breakthrough cancer pain. 3 The “icing on the cake” of the bribery scheme was the “speaker program,” id. at 17, in which Insys paid selected physicians—in particular those specializing in pain medicine and prescribing Subsys off-label—hefty honoraria to speak at dinner meetings Insys’ representatives hosted. The purpose of

1 Insys was a publicly held pharmaceutical firm. Simon, 12 F.4th at 15.

2 The defendants were also found guilty of mail fraud and wire fraud, which

constituted the predicate acts underlying the RICO offense. Four of the defendants were found guilty of honest services mail and wire fraud. Those acts also constituted predicate acts. 3 The term ‘‘breakthrough cancer pain’’ is a term of art: it refers to brief spikes

in pain (typically lasting less than one hour) in patients with cancer who are already dealing with constant and relatively steady pain. All other uses of Subsys were deemed ‘‘off-label.’’ Simon, 12 F.4th at 15.

USCA11 Case: 22-14192 Document: 108-1 Date Filed: 08/18/2026 Page: 3 of 32

22-14192 Opinion of the Court 3

these speaker programs was ostensibly to introduce Subsys to physicians in the community, but their true purpose was to put cash in the hands of the prescribing physicians.

Michael Babich, Insys’ President and Chief Executive Officer , and Alec Burlakoff, Insys’ Vice President of Sales, pleaded guilty to the RICO conspiracy 4 and testified as prosecution witnesses at the trial. Burlakoff referred to the speakers, including Dr. Steven Chun, an appellant here, as “whales”:

physicians who “had agreed in a very clear and concise manner that they were up for the deal, which meant that they would be compensated based on the number of prescriptions of Subsys they wrote. A corollary to that deal was that “the more they wrote and the more they increased the dose, the more they’d get paid to speak.” At Burlakoff’s urging, regional sales managers were to have a “candid conversation” with each potential whale and make clear that if the physician was going to receive payments from Insys, he was “going to write a significant amount of Subsys prescriptions to new patients as well as increase the doses of current patients.” Burlakoff told sales managers to view speakers as their “business partners.”

4 Burlakoff pleaded guilty to the RICO conspiracy. On January 23, 2020, the

District Court sentenced him to 26 months in prison and a three years of supervised release. USA v. Babich et al., 1:16-cr-10343, ECF No. 1313 (D. Mass. Jan. 10, 2019).

4 Opinion of the Court 22-14192

Id. at 18 (alterations adopted). As for the speaker program, Burlako ff had this to say:

[T]he speaking events themselves had little to no attendance . Often, only the speaker, a friend or family member, and the sales representative were on hand. Even when more people were in attendance, the speaker programs were mostly “social outings” or “just a reason to gather people and have dinner and pay [the doctor].” Although sales representatives were required to submit sign-in forms and attendee evaluation forms to a third-party compliance firm (Sci Medica), they frequently submitted inaccurate documentation , including sign-in sheets with names and signatures of people who were not present, to give the speaking programs an aura of legitimacy.

Id. at 19. The dinners were obvious shams. They were created to hide the fact that the honoraria Insys paid the speakers violated the “Anti-Kickback Statute,” 42 U.S.C. § 1320a-7b(b), which prohibits the payment or receipt of kickbacks in connection with a federal healthcare program, such as Medicare.

The jury returned verdicts against the founder of Insys and four of its executives on May 2, 2019. USA v. Babich et al., 1:16-cr- 10343, ECF No. 841 (D. Mass. Jan. 10, 2019). This brings us to the case at hand.

* * *

On March 12, 2020, a Middle District of Florida grand jury returned an indictment against Steven Chun and Daniel Tondre.

22-14192 Opinion of the Court 5

The grand jury superseded the indictment on February 5, 2022— 34 months later. The superseded version charged the defendants with committing 16 separate offenses, all based on the bribery scheme involved in Simon.

Count One alleged that, from August 2012 through July 2015, six individuals conspired in violation of 18 U.S.C. § 371 to violate the Anti-Kickback Statute by soliciting or receiving bribes for prescribing Subsys. Those six individuals were (1) Chun, a physician specializing in pain medicine and an enrolled Medicare provider ; (2) Tondre, a sales representative and trainer for Insys whose sales territory included Chun and his medical practice; (3) Babich, Insys’ President and Chief Executive Officer; (4) Burlakoff, Insys’ Vice President of Sales; (5) Liz Gurrieri, an Insys technician; and (6) Pharmacist 1, who filled Chun’s prescriptions.

Counts Two through Six alleged that, between May 4 and June 22, 2015, Tondre violated the Anti-Kickback Statute by paying Chun a bribe for prescribing Subsys. Counts Seven through Eleven alleged that Chun violated the Anti-Kickback Statute by accepting payments for writing Subsys prescriptions. Counts Twelve through Sixteen alleged that Chun on two occasions and Tondre on five committed identification fraud—using without authority the identification of another—between April 4 and June 16, 2015, in violation of 18 U.S.C. § 1028(a)(7).

USCA11 Case: 22-14192 Document: 108-1 Date Filed: 08/18/2026 Page: 6 of 32

6 Opinion of the Court 22-14192

Chun and Tondre entered pleas of not guilty to both indictments and stood trial before a jury on May 9, 2022. 5 The Government rested its case on May 19, and Chun did likewise. Tondre chose to testify at trial. At the close of the evidence, the defendants moved the District Court for judgment of acquittal. 6 The Court denied their motions. The jury found Chun guilty on Counts One and Seven through Eleven and Tondre guilty on Counts One through Six, Twelve, and Sixteen. Following the District Court’s imposition of their sentences,7 Chun and Tondre appealed their convictions and sentences.

Both Chun and Tondre challenge the District Court’s denial of the motions for judgment of acquittal. We discuss the Court’s ruling in Part I. In Part II, we consider the District Court’s handling of two notes the jury submitted to the Court during deliberations.

5 On the eve of trial, the District Court, on the Government’s motion, dis-

missed Counts Thirteen though Fifteen pending against Chun and Tondre. 6 See Fed. R. Crim. P. 29(a). On May 23, the Court granted Chun’s motion as

to Counts Twelve and Sixteen. 7 After denying Chun’s Rule 29(c) and Rule 53 alternative motions for judg-

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Steven Chun, (11th Cir. 2026).

United States v. Steven Chun (United States v. Steven Chun) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Samir S. Najjar
283 F.3d 1306 (Eleventh Circuit, 2002)
Access Now, Inc. v. Southwest Airlines Co.
385 F.3d 1324 (Eleventh Circuit, 2004)
United States v. Richard Junior Frazier
387 F.3d 1244 (Eleventh Circuit, 2004)
United States v. Michael Devegter
439 F.3d 1299 (Eleventh Circuit, 2006)
United States v. Billy Jack Keene
470 F.3d 1347 (Eleventh Circuit, 2006)
United States v. Browne
505 F.3d 1229 (Eleventh Circuit, 2007)
United States v. Lopez
590 F.3d 1238 (Eleventh Circuit, 2009)
Quercia v. United States
289 U.S. 466 (Supreme Court, 1933)
United States v. Rivera-Santiago
107 F.3d 960 (First Circuit, 1997)
United States v. Arturo Rodriguez, Vincente Ramirez
765 F.2d 1546 (Eleventh Circuit, 1985)
Cavazos v. Smith
132 S. Ct. 2 (Supreme Court, 2011)
United States v. Chris Vernon
723 F.3d 1234 (Eleventh Circuit, 2013)
United States v. Carlos Rodriguez Nerey
877 F.3d 956 (Eleventh Circuit, 2017)
United States v. Keenan Joyner
882 F.3d 1369 (Eleventh Circuit, 2018)
United States v. Jarred Alexander Goldman
953 F.3d 1213 (Eleventh Circuit, 2020)
United States v. Simon
12 F.4th 1 (First Circuit, 2021)
United States v. Shah
95 F.4th 328 (Fifth Circuit, 2024)
United States v. Jordan Jysae Pulido
133 F.4th 1256 (Eleventh Circuit, 2025)